The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers
2016
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
3
Citations
NaN
KQI